Should You Buy I-Mab ADR (IMAB) Stock on Wednesday?

The market has been high on I-Mab ADR (IMAB) stock recently. IMAB gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

I-Mab ADR has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IMAB!

See Full IMAB Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With IMAB Stock Today?

I-Mab ADR (IMAB) stock is trading at $1.49 as of 1:25 PM on Wednesday, Nov 1, a gain of $0.06, or 3.85% from the previous closing price of $1.43. The stock has traded between $1.36 and $1.54 so far today. Volume today is 544,147 compared to average volume of 647,959. To see InvestorsObserver's Sentiment Score for I-Mab ADR click here.

More About I-Mab ADR

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia. Click Here to get the full Stock Report for I-Mab ADR stock.